Evidence map›Paper›PMID 34758330›Full record

ArticleCell reports2021

TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.

Aishwarya Payapilly, Ryan Guilbert, Tine Descamps, Gavin White, Peter Magee, Cong Zhou, Alastair Kerr, Kathryn L Simpson, Fiona Blackhall, Caroline Dive and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. CSDE1 Drives Glycolysis and the Progression of Prostate Cancer Through RAC1-Dependent RAS/MAPK Activation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Photoactivatable Nanobody Conjugate Dimerizer Temporally Resolves Tiam1-Rac1 Signaling Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  13. Article
  14. Article
  15. A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Aishwarya PayapillyCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.
Ryan GuilbertCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.
Tine DescampsCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; Cancer Research UK Manchester Institute Cancer Biomarker Centre, The University of Manchester, Alderley Park SK10 4TG, UK.
Gavin WhiteCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.
Peter MageeCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.
Cong ZhouCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; Cancer Research UK Manchester Institute Cancer Biomarker Centre, The University of Manchester, Alderley Park SK10 4TG, UK.
Alastair KerrCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; Cancer Research UK Manchester Institute Cancer Biomarker Centre, The University of Manchester, Alderley Park SK10 4TG, UK.
Kathryn L SimpsonCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; Cancer Research UK Manchester Institute Cancer Biomarker Centre, The University of Manchester, Alderley Park SK10 4TG, UK.
Fiona BlackhallCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Caroline DiveCancer Research UK Lung Cancer Centre of Excellence, Manchester, UK; Cancer Research UK Manchester Institute Cancer Biomarker Centre, The University of Manchester, Alderley Park SK10 4TG, UK.
Angeliki MalliriCell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK. Electronic address: angeliki.malliri@cruk.manchester.ac.uk.
Cancer Research UK · GB

Funding

Cancer Research UK 19278Cancer Research UK 20410Wellcome Trust
6 · The paper itself

Abstract

Small-cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, has limited treatment options beyond platinum-based chemotherapy, whereafter acquired resistance is rapid and common. By analyzing expression data from SCLC tumors, patient-derived models, and established cell lines, we show that the expression of TIAM1, an activator of the small GTPase RAC1, is associated with a neuroendocrine gene program. TIAM1 depletion or RAC1 inhibition reduces viability and tumorigenicity of SCLC cells by increasing apoptosis associated with conversion of BCL2 from its pro-survival to pro-apoptotic function via BH3 domain exposure. This conversion is dependent upon cytoplasmic translocation of Nur77, an orphan nuclear receptor. TIAM1 interacts with and sequesters Nur77 in SCLC cell nuclei and TIAM1 depletion or RAC1 inhibition promotes Nur77 translocation to the cytoplasm. Mutant TIAM1 with reduced Nur77 binding fails to suppress apoptosis triggered by TIAM1 depletion. In conclusion, TIAM1-RAC1 signaling promotes SCLC cell survival via Nur77 nuclear sequestration.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell ProliferationFemaleGene Expression ProfilingHumansLung NeoplasmsMiceMice, Inbred NODMice, SCIDNuclear Receptor Subfamily 4, Group A, Member 1Protein ConformationProto-Oncogene Proteins c-bcl-2rac1 GTP-Binding ProteinBCL2 protein, humanBiomarkers, TumorNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Proto-Oncogene Proteins c-bcl-2rac1 GTP-Binding ProteinRAC1 protein, humanTIAM1 protein, humanT-Lymphoma Invasion and Metastasis-inducing Protein 1apoptosisBCL2neuroendocrineNur77RACSCLCsmall cell lung cancerTIAM1

Identifiers

PMID34758330
PMCPMC8595642
OpenAlexW3212622670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.